anti-CD19 CAR T-cell therapy (University of Utah)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (University of Utah)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsImmunostimulantsT lymphocytes stimulants

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe University Of Utah

China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Utah

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A